Godfrey JR, Lawrence RA. Toward optimal health: the maternal benefits of breastfeeding. J Women’s Health (2002). 2010;19(9):1597–602.

Article  Google Scholar 

Chowdhury R, Sinha B, Sankar MJ, Taneja S, Bhandari N, Rollins N, et al. Breastfeeding and maternal health outcomes: a systematic review and meta-analysis. Acta Paediatr. 2015;104(467):96–113.

Article  PubMed  PubMed Central  Google Scholar 

Ip S, Chung M, Raman G, Chew P, Magula N, DeVine D, et al. Breastfeeding and maternal and infant health outcomes in developed countries. Evid Rep Technol Assess. 2007;153:1–186.

Google Scholar 

Ip S, Chung M, Raman G, Trikalinos TA, Lau J. A summary of the Agency for Healthcare Research and Quality’s evidence report on breastfeeding in developed countries. Breastfeed Med. 2009;4(Suppl 1):S17-30.

Article  PubMed  Google Scholar 

Chantry CJ, Howard CR, Auinger P. Full breastfeeding duration and associated decrease in respiratory tract infection in US children. Pediatrics. 2006;117(2):425–32.

Article  PubMed  Google Scholar 

Greer FR, Sicherer SH, Burks AW. Effects of early nutritional interventions on the development of atopic disease in infants and children: the role of maternal dietary restriction, breastfeeding, timing of introduction of complementary foods, and hydrolyzed formulas. Pediatrics. 2008;121(1):183–91.

Article  PubMed  Google Scholar 

Mazer-Amirshahi M, Samiee-Zafarghandy S, Gray G, van den Anker JN. Trends in pregnancy labeling and data quality for US-approved pharmaceuticals. Am J Obstet Gynecol. 2014;211(6):690.e1-11.

Article  PubMed  Google Scholar 

Jones H, Rowland-Yeo K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacomet Syst Pharmacol. 2013;2(8): e63.

Article  Google Scholar 

Yeung CHT, Ito S, Autmizguine J, Edginton AN. Incorporating breastfeeding-related variability with physiologically based pharmacokinetic modeling to predict infant exposure to maternal medication through breast milk: A workflow applied to lamotrigine. AAPS J. 2021;23(4):70.

Article  CAS  PubMed  Google Scholar 

Yeung CHT, Fong S, Malik PRV, Edginton AN. Quantifying breast milk intake by term and preterm infants for input into paediatric physiologically based pharmacokinetic models. Matern Child Nutr. 2020;16(2): e12938.

Article  PubMed  PubMed Central  Google Scholar 

Bennett PN, Notrianni LJ. Risk from drugs in breast milk: an analysis by relative dose. Br J Clin Pharmacol. 1996;42:623–4.

Google Scholar 

National Institutes of Health Clinical Center (CC). Higher-Dose Ezetimibe to Treat Homozygous Sitosterolemia. 2008 [cited 6 Feb 2023]. https://clinicaltrials.gov/ct2/show/NCT00099996.

European Medicines Agency. Ezetimibe tablet 10 mg product-specific bioequivalence guidance. European Medicines Agency; 2018.

Google Scholar 

Kosoglou T, Maxwell S, Chung C, Batra V, Statkevich P. Dose-proportionality of ezetimibe. Clin Pharmacol Ther. 2002;71(2):P97.

Google Scholar 

Pharmacutical and Food Safety Bureau. Report on the Deliberation Results-Zetia Tablets 10 mg. Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour, and Welfare; 2007.

Google Scholar 

Schering-Plough. Review Report-Zetia Tablets 10 mg. Pharmaceutical and Medical Devices Agency; 2003.

Google Scholar 

Van Heek M, France CF, Compton DS, McLeod RL, Yumibe NP, Alton KB, et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther. 1997;283(1):157–63.

PubMed  Google Scholar 

Patrick JE, Kosoglou T, Stauber KL, Alton KB, Maxwell SE, Zhu Y, et al. Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab Dispos. 2002;30(4):430–7.

Article  CAS  PubMed  Google Scholar 

Oswald S, Haenisch S, Fricke C, Sudhop T, Remmler C, Giessmann T, et al. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin Pharmacol Ther. 2006;79(3):206–17.

Article  CAS  PubMed  Google Scholar 

Oswald S, König J, Lütjohann D, Giessmann T, Kroemer HK, Rimmbach C, et al. Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1. Pharmacogenet Genomics. 2008;18(7):559–68.

Article  CAS  PubMed  Google Scholar 

de Waart DR, Vlaming ML, Kunne C, Schinkel AH, Oude Elferink RP. Complex pharmacokinetic behavior of ezetimibe depends on abcc2, abcc3, and abcg2. Drug Metab Dispos Biol Fate Chem. 2009;37(8):1698–702.

Article  PubMed  Google Scholar 

MSP Singapore Co. Clinical pharmacology and biopharmaceutics review(s)—ZETIA. Center for Drug Evaluation and Research; 2001.

Google Scholar 

Sanis Health Inc. Ezetimibe Tablets Package Insert Product Monograph. Sanis Health Inc.; 2014.

Google Scholar 

Drugs and Lactation Database (LactMed®): Ezetimibe. 19 Oct 2020.

Guo L, Wang MM, He M, Qiu FR, Jiang J. Simultaneous determination of ezetimibe and its glucuronide metabolite in human plasma by solid phase extraction and liquid chromatography-tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci. 2015;986–987:108–14.

Article  Google Scholar 

Broughton PM. Carry-over in automatic analysers. J Autom Chem. 1984;6(2):94–5.

Article  CAS  Google Scholar 

Maharaj AR, Barrett JS, Edginton AN. A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam. AAPS J. 2013;15(2):455–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci. 2005;94(6):1259–76.

Article  CAS  PubMed  Google Scholar 

Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 2006;95(6):1238–57.

Article  CAS  PubMed  Google Scholar 

Rodgers T, Rowland M. Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res. 2007;24(5):918–33.

Article  CAS  PubMed  Google Scholar 

Schmitt W. General approach for the calculation of tissue to plasma partition coefficients. Toxicol In Vitro. 2008;22(2):457–67.

Article  CAS  PubMed  Google Scholar 

Ghosal A, Hapangama N, Yuan Y, Achanfuo-Yeboah J, Iannucci R, Chowdhury S, et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia). Drug Metab Dispos. 2004;32(3):314–20.

Article  CAS  PubMed  Google Scholar 

Shiran MR, Proctor NJ, Howgate EM, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A. Prediction of metabolic drug clearance in humans: in vitro-in vivo extrapolation vs allometric scaling. Xenobiotica. 2006;36(7):567–80.

Article  CAS  PubMed  Google Scholar 

Rostami-Hodjegan A, Tucker GT. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov. 2007;6(2):140–8.

Article  CAS  PubMed  Google Scholar 

Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet. 2005;20(6):452–77.

Article  CAS  PubMed  Google Scholar 

Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes. Drug Metab Pharmacokinet. 2006;21(5):357–74.

Article  CAS  PubMed  Google Scholar 

Nishimura M, Yaguti H, Yoshitsugu H, Naito S, Satoh T. Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2003;123(5):369–75.

Article  CAS  PubMed  Google Scholar 

Achour B, Dantonio A, Niosi M, Novak JJ, Fallon JK, Barber J, et al. Quantitative characterization of major hepatic UDP-glucuronosyltransferase enzymes in human liver microsomes: comparison of two proteomic methods and correlation with catalytic activity. Drug Metab Dispos. 2017;45(10):1102–12.

Article  CAS  PubMed  Google Scholar 

Prasad B, Johnson K, Billington S, Lee C, Chung GW, Brown CD, et al. Abundance of drug transporters in the human kidney cortex as quantified by quantitative targeted proteomics. Drug Metab Dispos. 2016;44(12):1920–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Food and Drug Administration. Guidance for industry—dissolution testing of immediate release solid oral dosage forms. Center for Drug Evaluation and Research; 1997.

Google Scholar 

Burt HJ, Riedmaier AE, Harwood MD, Crewe HK, Gill KL, Neuhoff S. Abundance of hepatic transporters in caucasians: a meta-analysis. Drug Metab Dispos. 2016;44(10):1550–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Willmann S, Höhn K, Edginton A, Sevestre M, Solodenko J, Weiss W, et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn. 2007;34(3):401–31.

Article  PubMed  Google Scholar 

Edginton AN, Schmitt W, Willmann S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet. 2006;45(10):1013–34.

Article  CAS  PubMed  Google Scholar 

Edginton AN, Schmitt W, Voith B, Willmann S. A mechanistic approach for the scaling